Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,500
- 试验地点
- 52
- 主要终点
- Functional Outcome: Characterize Change Using Early Treatment of Diabetic Retinopathy Study (ETDRS) / HOTV Best Corrected Visual Acuity (BCVA) letter score
研究概览
简要总结
This is an international, multicenter study with two components:
Registry
- A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection
- Enrollment is open to all genes on the RD Rare Gene List
Natural History Study
- A prospective, standardized, longitudinal Natural History Study
- Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows.
Registry Objectives
- Genotype Characterization
- Cross-Sectional Phenotype Characterization (within gene)
- Establish a Link to My Retina Tracker Registry (MRTR)
- Ancillary Exploratory Studies - Pooling of Genes
Natural History Study Objectives
- Natural History (within gene)
- Structure-Function Relationship (within gene)
- Risk Factors for Progression (within gene)
- Ancillary Exploratory Studies - Pooling of Genes
详细描述
This study includes multiple phases.
- Screening Phase
The patient's current genetic report will be reviewed. Genetic testing will not be performed in this study. A prior conclusive genetic test will be assessed for screening analysis. Having at least one gene on the RD Rare Gene List meets one of the eligible Genetic Screening Criteria and other eligibility criteria can be evaluated based on medical history. 2. Genetic Screening Phase:
Genetic reports for participants enrolled into the genetic screening phase will be uploaded to study website for review and confirmation by Central Genetics Auditor (CGA) as meeting Genetic Screening Criteria.Participants confirmed as meeting those criteria will be considered enrolled into the Registry. 3. Registry Phase:
The flow of participants who are enrolled into the Registry depends on whether their causal gene is designated as a Natural History Study (NHS) Target Gene. If they are not Designated as NHS Target Gene, they will receive annual phone calls up to 48 months from the Registry/Screening visit or until the gene is designated as NHS Target Gene. If they are Designated as NHS Target Gene participants will be considered pending enrollment into the NHS.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 4 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must meet all the following inclusion criteria at the Registry/Screening Visit to be eligible to enroll into the genetic screening phase:
- •Willing to participate in the study and able to communicate consent during the consent process
- •Willing and able to complete all applicable Registry/Screening Visit assessments
- •Age ≥ 4 years
- •Must have a single gene on the RD Rare Gene List which meets one of the Genetic Screening Criteria below based on a genetic report* from a clinically certified lab (or from a research lab which has been approved by the study Genetics Committee):
- •Inheritance Pattern is Recessive and has at least 2 disease-causing variants which are homozygous or heterozygous in trans
- •Inheritance Pattern is Recessive and has 2 disease-causing variants with unknown phase and meets all the following additional informatic criteria that is consistent with likely segregation in trans:
- •Investigator confirms genotype and phenotype are consistent with autosomal recessive inheritance
- •The 2 disease-causing variants have not been reported in cis in variant databases
- •No additional potentially pathogenic variants were found on the gene (and the sequencing data for the gene were sufficiently robust to detect any additional potentially pathogenic variants)
- •No potentially pathogenic variants were found in other common, likely candidate genes for the proposed condition
- •Inheritance Pattern is Dominant, X-linked, or Mitochondrial and has at least 1 disease-causing variant
- •Both eyes must meet the following criteria at the Registry/Screening Visit to enroll into the genetic screening phase:
- •Both eyes must have a clinical diagnosis of retinal dystrophy
- •Both eyes must permit good quality photographic imaging (e.g., but not limited to, clear ocular media, adequate pupil dilation, stable fixation)
排除标准
- •Participants must not meet any of the following exclusion criteria at the Registry/Screening Visit to be eligible to enroll into the genetic screening phase:
- •1. History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy including amiodarone, chloroquine, deferoxamine, hydroxychloroquine, pentosan polysulfate, tamoxifen, and deferoxamine Note: Since this is an observational study, pregnant women will not be specifically excluded from participation. However, minors that are pregnant shall be precluded from participation until they become the age of majority.
- •Ocular Exclusion Criteria:
- •If either eye has any of the following ocular exclusion criteria at the Registry/Screening Visit, then the participant is not eligible to enroll into the genetic screening phase:
- •Current vitreous hemorrhage
- •Current complications of pathological myopia (for example, but not limited to, myopic maculopathy including atrophy, scar, choroidal neovascularization, schisis) that could inhibit ability to obtain good quality photographic imaging
- •History of intraocular surgery (for example, but not limited to, cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within 3 months of Registry/Screening Visit
- •Current or any history of confirmed diagnosis of glaucoma (for example, but not limited to, glaucomatous VF changes or nerve changes, or history of glaucoma filtering surgery)
- •Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy
- •History or current evidence of ocular disease that, in the opinion of the Investigator, may confound assessment of visual function (for example, but not limited to, tractional or rhegmatogenous retinal detachment, any vitreoretinal surgery, retinal vascular occlusion, proliferative diabetic retinopathy)
- •The following medications and treatments are prohibited as they can affect progression of retinitis pigmentosa (RP). The participant must not have received the following treatments:
- •Any use of ocular stem cell or gene therapy Any treatment with ocriplasmin Treatment with Ozurdex (dexamethasone), Iluvien, or Yutiq (fluocinolone acetonide) intravitreal implant
- •The following medications and treatments are excluded within the specified timeframe:
- •Treatment with an ophthalmic oligonucleotide within the last 9 months (last treatment date is less than 9 months prior to Registry/Screening Visit date)
- •Treatment with any other product within five times the expected half-life of the product (time from last treatment date to Registry/Screening Visit date is at least 5 times the half-life of the given product)
研究组 & 干预措施
Younger Age Cohort
Participants ages ≥ 4 years and < 8 years old will be designated as the Younger Age Cohort.
- Participants in this cohort will not be assigned a Vision Cohort.
- Registry/Screening Visit and Natural History Study Visits will have an abbreviated testing schedule, detailed in the Schedule of Study Visits and Procedures table.
Vision Cohort 1
Participants who are aged ≥ 8 years old will be designated into a Vision Cohort based on data in the better eye, at the Registry/Screening Visit. Criteria that must be met in the better eye* at the Registry/Screening Visit: visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field** diameter 10 degrees or more in every meridian of the central field
Vision Cohort 2
Participants who are aged ≥ 8 years old will be designated into a Vision Cohort based on data in the better eye, at the Registry/Screening Visit. Criteria that must be met in the better eye* at the Registry/Screening Visit: visual acuity ETDRS letter score of 19-53 (approximate Snellen equivalent 20/100 to 20/400) or visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field** diameter less than 10 degrees in any meridian of the central field
Vision Cohort 3
Participants who are aged ≥ 8 years old will be designated into a Vision Cohort based on data in the better eye, at the Registry/Screening Visit. Criteria that must be met in the better eye* at the Registry/Screening Visit: visual acuity ETDRS letter score of 18 or less (approximate Snellen equivalent 20/500 or worse)
结局指标
主要结局
Functional Outcome: Characterize Change Using Early Treatment of Diabetic Retinopathy Study (ETDRS) / HOTV Best Corrected Visual Acuity (BCVA) letter score
时间窗: Baseline and every year until study completion (4 years)
Measured by Electronic Visual Acuity (EVA) system or ETDRS/HOTV charts
Functional Outcome: Characterize Change Using ETDRS/HOTV best corrected low luminance visual acuity letter score
时间窗: Baseline and every year until study completion (4 years)
Measured by Electronic Visual Acuity (EVA) system or ETDRS/HOTV charts
Functional Outcome: Characterize Change in Contrast sensitivity function
时间窗: Baseline and every year until study completion (4 years)
Measured by Contrast sensitivity CSV-1000E chart
Functional Outcome: Characterize Change in Full-field retinal sensitivity
时间窗: Baseline and every year until study completion (4 years)
Measured by Full-field stimulus threshold (FST) testing to blue, white, and red stimuli using Diagnosys Espion
Functional Outcome: Characterize Change in Color vision function
时间窗: Baseline and every year until study completion (4 years)
Measured by Color vision testing using Lanthony D15
Functional Outcome: Characterize Change in Retinal function using amplitudes and timing in response to rod- and cone-specific stimuli
时间窗: Baseline and at study completion (4 years)
Measured by Full-field Electroretinogram (ffERG) Diagnosys Espion
Structural Outcome: Characterize Change in Ellipsoid zone (EZ) area; outer nuclear layer and ganglion cell layer thicknesses
时间窗: Baseline and every year until study completion (4 years)
Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) using Heidelberg Spectralis
Functional Outcome: Characterize change using Visual field sensitivity measured with quantitative topographic analysis (hill of vision [HOV])
时间窗: Baseline and every year until study completion (4 years)
Measured by Static Perimetry (SP) using Octopus 900 Pro
Functional Outcome: Characterize Change Using Low visual acuity test - for participants unable to see ETDRS letters
时间窗: Baseline and every year until study completion (4 years)
Measured by Berkeley Rudimentary Vision Test (BRVT) for Low Visual Acuity
Functional Outcome: Characterize Change in Mean retinal sensitivity
时间窗: Baseline and every year until study completion (4 years)
Measured by Fundus guided Microperimetry (MP) using MAIA
Structural Outcome: Characterize Change Using Qualitative and quantitative assessments of autofluorescence pattern
时间窗: Baseline and every year until study completion (4 years)
Measured by Fundus Autofluorescence (FAF) using Optos
次要结局
未报告次要终点